ArticlePLoS pathogens2011
CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.
Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 95 citations in OpenAlex.
- Oral live attenuated polio vaccines induce enhanced T-cell responses with broad antigen recognition compared to inactivated polio vaccines.Clinical immunology (Orlando, Fla.) · 2026Trial
- Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination.Science translational medicine · 2016Trial
- Varicella zoster virus infection.Nature reviews. Disease primers · 2026Review
- Evaluation of a multiantigen mRNA vaccine against EEHV1A in Asian elephants.Journal of virology · 2026Article
- First evidence of clinical protection from an EEHV1A mRNA vaccine in naturally infected juvenile elephants.Journal of virology · 2026Article
- A modular nanoparticle display strategy for varicella-zoster virus gE based on a licensed protein scaffold.PLoS pathogens · 2026Article
- Potent and Long-Lasting Immunogenicity Generated by LNP-mRNA gE Antigen Against Varicella Zoster Virus via an AI-Assisted Pipeline.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Discovery of a small molecule TLR3 agonist adjuvant.Nature communications · 2025Article
- Effect of Different Adjuvants on the Immunogenicity of a Recombinant Herpes Zoster Vaccine in Mice, Rats and Non-Human Primates.Vaccines · 2025Article
- Research Progress on Varicella-Zoster Virus Vaccines.Vaccines · 2025Review
- Animal models of human herpesvirus infection.Animal models and experimental medicine · 2025Review
- The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer.Human vaccines & immunotherapeutics · 2024Review
- Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques.Emerging microbes & infections · 2024Article
- VZV Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation in Children: When to Stop?Cancer reports (Hoboken, N.J.) · 2024Article
- Management of a major varicella zoster exposure in a pediatric oncology population.Pediatric hematology and oncology · 2024Article
- Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine.NPJ vaccines · 2024Article
- Varicella-zoster virus recapitulates its immune evasive behaviour in matured hiPSC-derived neurospheroids.Frontiers in immunology · 2024Article
- A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates.Frontiers in immunology · 2024Article
- Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice.International journal of nanomedicine · 2024Article
- Immunogenicity in Mice Immunized with Recombinant Adenoviruses Expressing Varicella-Zoster Virus Envelope Glycoprotein E.Viruses · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Primary infection with varicella zoster virus (VZV) results in varicella (more commonly known as chickenpox) after which VZV establishes latency in sensory ganglia. VZV can reactivate to cause herpes zoster (shingles), a debilitating disease that affects one million individuals in the US alone annually. Current vaccines against varicella (Varivax) and herpes zoster (Zostavax) are not 100% efficacious. Specifically, studies have shown that 1 dose of varivax can lead to breakthrough varicella, albeit rarely, in children and a 2-dose regimen is now recommended. Similarly, although Zostavax results in a 50% reduction in HZ cases, a significant number of recipients remain at risk. To design more efficacious vaccines, we need a better understanding of the immune response to VZV. Clinical observations suggest that T cell immunity plays a more critical role in the protection against VZV primary infection and reactivation. However, no studies to date have directly tested this hypothesis due to the scarcity of animal models that recapitulate the immune response to VZV. We have recently shown that SVV infection of rhesus macaques models the hallmarks of primary VZV infection in children. In this study, we used this model to experimentally determine the role of CD4, CD8 and B cell responses in the resolution of primary SVV infection in unvaccinated animals. Data presented in this manuscript show that while CD20 depletion leads to a significant delay and decrease in the antibody response to SVV, loss of B cells does not alter the severity of varicella or the kinetics/magnitude of the T cell response. Loss of CD8 T cells resulted in slightly higher viral loads and prolonged viremia. In contrast, CD4 depletion led to higher viral loads, prolonged viremia and disseminated varicella. CD4 depleted animals also had delayed and reduced antibody and CD8 T cell responses. These results are similar to clinical observations that children with agammaglobulinemia have uncomplicated varicella whereas children with T cell deficiencies are at increased risk of progressive varicella with significant complications. Moreover, our studies indicate that CD4 T cell responses to SVV play a more critical role than antibody or CD8 T cell responses in the control of primary SVV infection and suggest that one potential mechanism for enhancing the efficacy of VZV vaccines is by eliciting robust CD4 T cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.